Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-10-22, Stock:ABBV, The news for the past five days is as follows:
2018-10-15: NEWS1: IMPORTANT DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.NEWS2: SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline – ABBV.NEWS3: CLASS ACTION UPDATE for COCP, ABBV and ALNY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders.NEWS4: Merck Is Expected to Record Steady Revenue Growth in Q3.NEWS5: Company News For Oct 15, 2018.NEWS6: Company News For Oct 15, 2018.NEWS7: Company News For Oct 15, 2018.NEWS8: AbbVie Inc. Investor Alert: Law Offices of Andrew J. Brown Investigates Possible Breaches of Fiduciary Duty by Officers and Directors.NEWS9: 2 Pharmaceutical Stocks to Buy With Dividends of 3% or Better.NEWS10: 2 Pharmaceutical Stocks to Buy With Dividends of 3% or Better.NEWS11: Health Canada Approves Label Update for AbbVie's HUMIRA® (adalimumab) Supporting Potential For Use During Breastfeeding and Use During Pregnancy if Clearly Needed.
2018-10-16: NEWS1: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AbbVie Inc. (ABBV).NEWS2: AbbVie Rises 3%.NEWS3: Drug-Price Transparency Won’t End the Patent Games.NEWS4: AbbVie Reinforces Leadership in Gastroenterology with New Data Showcasing Research Advancements Across Robust Portfolio at United European Gastroenterology (UEG) Week 2018.NEWS5: Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU.NEWS6: How Analysts View Merck Stock, Pre-Q3 Results.NEWS7: [$$] Biosimilar Humira Goes on Sale in Europe, Widening Gap With U.S..NEWS8: [$$] The Strategies AbbVie Employed to Protect Humira From Copycats.
2018-10-17: NEWS1: CORRECTING and REPLACING The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AbbVie Inc. (ABBV).NEWS2: SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against AbbVie Inc. - ABBV.NEWS3: SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline – ABBV.NEWS4: Amgen Launches Humira Biosimilar in Europe.NEWS5: EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq.NEWS6: EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq.NEWS7: EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq.NEWS8: AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA® (ibrutinib) in Combination with Obinutuzumab (GAZYVA®) for Previously Untreated Chronic Lymphocytic Leukemia (CLL).NEWS9: Samsung launches third rival to AbbVie's Humira drug in EU.NEWS10: [$$] By Adding Patents, Drugmaker Keeps Cheaper Humira Copies Out of U.S..
2018-10-18: NEWS1: Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.NEWS2: AbbVie Falls 3%.NEWS3: Hagens Berman Reminds Investors in AbbVie Inc. (NYSE: ABBV) of the Firm’s Ongoing Investigation and the November 20, 2018 Securities Class Action Lead Plaintiff Deadline.NEWS4: FDA Accepts Application for AbbVie's Imbruvica in Specific Blood Cancers.NEWS5: MTUM, ADBE, ABBV, NKE: ETF Outflow Alert.NEWS6: MTUM, ADBE, ABBV, NKE: ETF Outflow Alert.NEWS7: SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against AbbVie Inc. (ABBV) & Lead Plaintiff Deadline – November 20, 2018.NEWS8: AbbVie settles Humira biosimilar dispute with Fresenius Kabi.NEWS9: AbbVie settles Humira biosimilar dispute with Fresenius Kabi.NEWS10: AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Fresenius Kabi.NEWS11: Waltham&apos;s Morphic Therapeutic inks $100M deal with AbbVie.NEWS12: AbbVie and Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases.NEWS13: AbbVie Announces Resolution Of HUMIRA Patent Disputes With Fresenius Kabi.NEWS14: AbbVie Announces Resolution Of HUMIRA Patent Disputes With Fresenius Kabi.
2018-10-19: NEWS1: Investor Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AbbVie Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm.NEWS2: SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AbbVie Inc. of Class Action Lawsuit and Upcoming Deadline – ABBV.NEWS3: ABBV NOTICE ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against AbbVie Inc.; Important Deadline – ABBV.NEWS4: Noteworthy Friday Option Activity: SBNY, FRPT, ABBV.NEWS5: Noteworthy Friday Option Activity: SBNY, FRPT, ABBV.NEWS6: AbbVie CFO Chase to retire by mid-year 2019.NEWS7: AbbVie names Robert Michael chief financial officer.NEWS8: AbbVie CFO Bill Chase to retire.NEWS9: What to Expect from Thermo Fisher’s Third-Quarter Earnings.NEWS10: AbbVie CFO William Chase Plans To Retire In Mid-2019.NEWS11: AbbVie CFO William Chase Plans To Retire In Mid-2019.

Answer: Decrease